Automate Your Wheel Strategy on QDEL
With Tiblio's Option Bot, you can configure your own wheel strategy including QDEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QDEL
- Rev/Share 40.514
- Book/Share 41.2511
- PB 0.6802
- Debt/Equity 1.0
- CurrentRatio 1.1221
- ROIC -0.0099
- MktCap 1905288030.0
- FreeCF/Share 1.8213
- PFCF 15.4525
- PE -4.073
- Debt/Assets 0.4378
- DivYield 0
- ROE -0.156
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | QDEL | Jefferies | Hold | Buy | -- | $44 | May 8, 2025 |
| Upgrade | QDEL | Citigroup | Neutral | Buy | $44 | $50 | Dec. 11, 2024 |
| Initiation | QDEL | Jefferies | -- | Hold | -- | $43 | Dec. 10, 2024 |
| Resumed | QDEL | UBS | -- | Neutral | $42 | $50 | Sept. 19, 2024 |
| Upgrade | QDEL | Craig Hallum | Hold | Buy | $40 | $57 | Sept. 5, 2024 |
News
QuidelOrtho Completes Debt Refinancing
Published: August 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the completion of a series of related transactions to refinance its debt structure and support future growth. Through these transactions, the Company extended its debt maturities and reduced required amortization payments.
Read More
Science Bytes Podcast Explores How Diagnostics Can Help Protect Students and Communities
Published: August 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, is sharing timely public health insights from Dr. Jonathan Temte, Professor of Family Medicine and Community Health at the University of Wisconsin-Madison. In this 50th episode of QuidelOrtho Science Bytes, Dr. Temte outlines the seasonal challenges posed by influenza, RSV, COVID-19 and vaccine-preventable diseases such as measles and whooping cough.
Read More
QuidelOrtho Launches Certified Analyzer Program
Published: August 13, 2025 by: PRNewsWire
Sentiment: Neutral
Initiative to expand testing access to underserved U.S. communities SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiative designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. Tailored for clinics, physician office labs and small hospitals with fewer than 100 beds, the program offers certified VITROS™ analyzers that deliver proven reliability and quality results, with award-winning service, at a fraction of the cost.
Read More
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Should Value Investors Buy QuidelOrtho (QDEL) Stock?
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
QDEL stock rises 12.8% after Q2 earnings beat. Adjusted margins improve amid soft revenue and ongoing business headwinds.
Read More
Real Labs, Actual Decisions With Actionable Six Sigma Metrics
Published: July 17, 2025 by: PRNewsWire
Sentiment: Neutral
QuidelOrtho Announces Featured ADLM Session SAN DIEGO , July 17, 2025 /PRNewswire/ -- How can actionable, Six Sigma insights improve lab performance? In a featured session at the Association for Diagnostics & Laboratory Medicine (ADLM) meeting, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and a panel of experts will share how QuidelOrtho's Six Sigma tools and real lab data can drive quality outcomes.
Read More
QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)
Published: July 14, 2025 by: PRNewsWire
Sentiment: Neutral
Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms SAN DIEGO , July 14, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for fecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for fecal pancreatic elastase aids in the determination of pancreatic insufficiency.
Read More
Here's Why QuidelOrtho (QDEL) is a Strong Growth Stock
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Are Investors Undervaluing QuidelOrtho (QDEL) Right Now?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
QDEL continues to witness growth on the back of its strong product portfolio.
Read More
What Makes QuidelOrtho (QDEL) a New Buy Stock
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
QuidelOrtho (QDEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why QuidelOrtho (QDEL) is a Top Momentum Stock for the Long-Term
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why QuidelOrtho (QDEL) is a Strong Growth Stock
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
QuidelOrtho to Participate in Upcoming Investor Conferences
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45th Annual Growth Stock Conference, Wednesday, June 4, 2025 Members of QuidelOrtho's management team will participate in a presentation at 9:00 a.m. ET.
Read More
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
QDEL continues to witness growth on the back of its strong product portfolio.
Read More
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Despite a once promising future, QuidelOrtho Corporation's current prospects are unappealing. I rated QuidelOrtho as a "Buy" in July 2023, but the stock has since declined by ~60% as its growth has stagnated. On 05/07/2025 the company reported top and bottom-line beats for its Q1/2025 earnings, bumping its shares up >40%.
Read More
QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.
Read More
QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
QuidelOrtho Corporation (NASDAQ:QDEL ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Conor McNamara - RBC Capital Patrick Donnelly - Citi Andrew Brackmann - William Blair Jack Meehan - Nephron Research Lu Li - UBS Casey Woodring - JPMorgan Andrew Cooper - Raymond James Tycho Peterson - Jefferies Operator Welcome to the QuidelOrtho First Quarter 2025 Financial Results Conference Call and Webcast. At this time, all participant lines are in listen …
Read More
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
QuidelOrtho (QDEL) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.44 per share a year ago.
Read More
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.
Read More
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Read More
Why QuidelOrtho (QDEL) Could Beat Earnings Estimates Again
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
QuidelOrtho (QDEL) Surges 10.1%: Is This an Indication of Further Gains?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
QDEL continues to witness growth on the back of its strong product portfolio.
Read More
QuidelOrtho Unveils Results Manager System to Streamline Testing
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
QDEL introduces the Results Manager System, a powerful tool designed to streamline diagnostic data management, enhance efficiency, and improve patient care.
Read More
QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Despite solid performances by the Labs and Immunohematology units and China and Other regions, QDEL reports soft overall top-line results in fourth-quarter 2024.
Read More
QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
QuidelOrtho Corporation (NASDAQ:QDEL ) Q4 2024 Results Conference Call February 12, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Patrick Donnelly - Citi Bill Bonello - Craig-Hallum Lu Li - UBS Andrew Cooper - Raymond James Casey Woodring - JPMorgan Andrew Brackmann - William Blair Jose Ricardo - RBC Capital Markets Operator Welcome to the QuidelOrtho Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participant …
Read More
About QuidelOrtho Corporation (QDEL)
- IPO Date 1991-02-01
- Website https://www.quidelortho.com
- Industry Medical - Instruments & Supplies
- CEO Brian J. Blaser
- Employees 6600